What Is Tirzepatide?
Category: Peptide
A dual GLP-1/GIP receptor agonist for weight management and type 2 diabetes. Clinical trials showed up to 22.5% body weight reduction. Brand names include Mounjaro and Zepbound.
Detailed Explanation
Tirzepatide is a first-in-class dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist. FDA-approved as Mounjaro for type 2 diabetes and Zepbound for weight management, it activates two incretin hormone receptors simultaneously, producing superior metabolic effects compared to GLP-1-only agonists. The SURMOUNT clinical trials demonstrated unprecedented weight loss results of up to 22.5% of body weight, the most of any approved weight loss medication.
Practical Context
Tirzepatide is dosed once weekly via subcutaneous injection. The recommended titration starts at 2.5mg weekly for 4 weeks, then increases by 2.5mg every 4 weeks up to a maximum of 15mg weekly. Like semaglutide, slow titration is essential to minimize GI side effects. Tirzepatide requires refrigeration and has excellent stability after reconstitution (up to 6 weeks). It is important to maintain adequate protein intake and exercise during tirzepatide use to preserve lean muscle mass.
Frequently Asked Questions
Is tirzepatide better than semaglutide?
Head-to-head trials show tirzepatide produces greater weight loss (up to 22.5% vs 17%) and slightly better blood sugar control. However, semaglutide has more long-term safety data. Both are highly effective.
Related Peptides
- Tirzepatide - A dual GIP and GLP-1 receptor agonist for weight management. (Dosage | Calculator)
- Semaglutide - A GLP-1 receptor agonist used for weight management and blood sugar control. (Dosage | Calculator)
- AOD-9604 - A modified fragment of human growth hormone targeting fat metabolism. (Dosage | Calculator)
Related Terms
- GLP-1 (Glucagon-Like Peptide-1) - A gut hormone that regulates appetite, blood sugar, and gastric emptying. GLP-1 agonists like semaglutide and tirzepatide mimic this hormone for weight management.
- Semaglutide - A GLP-1 receptor agonist used for weight management and type 2 diabetes. The active ingredient in brand-name medications Ozempic and Wegovy. Administered once weekly.
- Titration - The process of gradually increasing a medication dose over time. Essential for GLP-1 agonists to minimize gastrointestinal side effects. Typically involves increasing the dose every 4 weeks.